188 related articles for article (PubMed ID: 30933891)
1. In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor.
Muellerleile LM; Buxbaum B; Nell B; Fux DA
Res Vet Sci; 2019 Jun; 124():233-238. PubMed ID: 30933891
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
3. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
[TBL] [Abstract][Full Text] [Related]
4. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
6. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
Dinç E; Ayaz L; Kurt AH
J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
[TBL] [Abstract][Full Text] [Related]
8. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
10. The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization.
Eski MT; Teberik K; Oltulu P; Ankaralı H; Kaya M; Alpay M
Hum Exp Toxicol; 2022; 41():9603271221084674. PubMed ID: 35465742
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
Kanda A; Noda K; Saito W; Ishida S
Sci Rep; 2015 Dec; 5():17946. PubMed ID: 26648523
[TBL] [Abstract][Full Text] [Related]
12. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
14. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
17. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
Lang GE; Lang GK; Deissler HL
Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
[TBL] [Abstract][Full Text] [Related]
18. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats.
Luaces-Rodríguez A; Del Amo EM; Mondelo-García C; Gómez-Lado N; Gonzalez F; Ruibal Á; González-Barcia M; Zarra-Ferro I; Otero-Espinar FJ; Fernández-Ferreiro A; Aguiar P
Eur J Pharm Biopharm; 2020 Sep; 154():330-337. PubMed ID: 32659326
[TBL] [Abstract][Full Text] [Related]
19. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
20. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
